SHORT MINI-FUTURE - BIOGEN IDEC | Delayed Deutsche Boerse AG 04:11:33 2024-05-22 EDT | ||
| 6.51 EUR | -2.25% |
|
| Current month | -12.94% | ||
| 1 month | -32.59% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 6.51 | -2.25% |
| 24-05-21 | 6.66 | +9.18% |
| 24-05-20 | 6.1 | -3.94% |
| 24-05-17 | 6.35 | +0.32% |
| 24-05-16 | 6.33 | +10.09% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 04:11 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VU911Q |
| ISIN | DE000VU911Q4 |
| Date issued | 2023-07-17 |
| Strike | 297.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.33 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.08 € |
|---|---|
| Lowest since issue | 1.18 € |
| Spread | 0.16 € |
| Spread % | 2.40% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
227.7
USD
Average target price
285.9
USD
Spread / Average Target
+25.57%
- Stock Market
- Certificates
- Certificat